{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:16:18Z","timestamp":1762978578626,"version":"3.37.3"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["zefq-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Zeitschrift f\u00fcr Evidenz, Fortbildung und Qualit\u00e4t im Gesundheitswesen"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.zefq.2017.04.001","type":"journal-article","created":{"date-parts":[[2017,5,13]],"date-time":"2017-05-13T16:15:42Z","timestamp":1494692142000},"page":"22-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Zeitliche Entwicklung der Anwendungspr\u00e4valenz von Statinen in Deutschland \u2013 Ergebnisse der nationalen Interview- und Untersuchungssurveys 1997-1999 und 2008-2011"],"prefix":"10.1016","volume":"122","author":[{"given":"Hildtraud C.","family":"Knopf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus A.","family":"Busch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Truthmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Schienkiewitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christa","family":"Scheidt-Nave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.zefq.2017.04.001_bib0305","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"Perk","year":"2012","journal-title":"Eur Heart J."},{"issue":"9438","key":"10.1016\/j.zefq.2017.04.001_bib0310","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.zefq.2017.04.001_bib0315","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1161\/CIRCULATIONAHA.109.830984","article-title":"Relations of lipid concentrations to heart failure incidence: the Framingham Heart Study","volume":"120","author":"Velagaleti","year":"2009","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.zefq.2017.04.001_bib0320","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12889-016-2826-2","article-title":"Changes in mean serum lipids among adults in Germany: results from National Health Surveys 1997-99 and 2008-11","volume":"16","author":"Truthmann","year":"2016","journal-title":"BMC Public Health."},{"issue":"25 suppl 2","key":"10.1016\/j.zefq.2017.04.001_bib0325","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","article-title":"2013 ACC\/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.zefq.2017.04.001_bib0330","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1365-2125.2005.02478.x","article-title":"Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003","volume":"60","author":"Walley","year":"2005","journal-title":"Br J Clin Pharmacol."},{"issue":"11","key":"10.1016\/j.zefq.2017.04.001_bib0335","doi-asserted-by":"crossref","first-page":"NP1","DOI":"10.1177\/2047487316653709","volume":"23","author":"Authors\/Task Force","year":"2016","journal-title":"Eur J Prev Cardiol."},{"issue":"4","key":"10.1016\/j.zefq.2017.04.001_bib0340","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1046\/j.1365-2125.2002.01562.x","article-title":"Time trends in lipid lowering drug use in The Netherlands. Has the backlog of candidates for treatment been eliminated?","volume":"53","author":"Mantel-Teeuwisse","year":"2002","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.zefq.2017.04.001_bib0345","unstructured":"Kuklina EV, Carroll MD, Shaw KM, Hirsch R. Trends in High LDL Cholesterol, Cholesterol-lowering Medication Use, and Dietary Saturated-fat Intake: United States, 1976-2010: U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, Centers for Disease Control and Prevention, National Center for Health Statistics; 2013. Available from: http:\/\/www.cdc.gov\/nchs\/data\/databriefs\/db117.pdf."},{"key":"10.1016\/j.zefq.2017.04.001_bib0350","doi-asserted-by":"crossref","unstructured":"H\u00e4ussler B, H\u00f6er A, Hempel E. Arzneimittel-Atlas 2014. Der Arzneimittelverbrauch in der GKV. Berlin Heidelberg: Springer- Verlag 2014. Available from: http:\/\/www.springer.com\/de\/book\/9783662434468.","DOI":"10.1007\/978-3-662-43447-5"},{"key":"10.1016\/j.zefq.2017.04.001_bib0355","unstructured":"Lasek R, Anlauf M, Eschenhagen T, Hauschke D, Hein L, Hense H, et al. Handlungsleitlinie Fettstoffwechselst\u00f6rungen aus Empfehlungen zur Therapie von Fettstoffwechselst\u00f6rungen. Arzneiverordnung in der Praxis [Internet]. 2012; Band 39(3. Auflage). Available from: http:\/\/www.akdae.de\/Arzneimitteltherapie\/TE\/A-Z\/PDF\/Fettstoffwechselstoerungen.pdf."},{"issue":"10059","key":"10.1016\/j.zefq.2017.04.001_bib0360","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet."},{"issue":"4","key":"10.1016\/j.zefq.2017.04.001_bib0365","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1734-1140(11)70601-6","article-title":"Statin-induced myopathies","volume":"63","author":"Tomaszewski","year":"2011","journal-title":"Pharmacol Rep."},{"issue":"6","key":"10.1016\/j.zefq.2017.04.001_bib0370","first-page":"631","article-title":"Review of Safety and Potential Side Effects","volume":"32","author":"Ramkumar","year":"2016","journal-title":"Acta Cardiol Sin."},{"key":"10.1016\/j.zefq.2017.04.001_bib0375","series-title":"Arzneiverordnungs-Report 2013","first-page":"686","article-title":"Lipidsenkende Mittel","author":"Klose","year":"2013"},{"issue":"11","key":"10.1016\/j.zefq.2017.04.001_bib0380","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.clinthera.2008.11.012","article-title":"Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel","volume":"30","author":"Chodick","year":"2008","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.zefq.2017.04.001_bib0385","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jama.288.4.495","article-title":"Elderly patients\u2019 adherence to statin therapy","volume":"288","author":"Applegate","year":"2002","journal-title":"JAMA."},{"issue":"2","key":"10.1016\/j.zefq.2017.04.001_bib0390","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1185\/030079903125002810","article-title":"Lipid-lowering therapy: strategies for improving compliance","volume":"20","author":"Riesen","year":"2004","journal-title":"Curr Med Res Opin."},{"issue":"4","key":"10.1016\/j.zefq.2017.04.001_bib0395","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.288.4.462","article-title":"Adherence with statin therapy in elderly patients with and without acute coronary syndromes","volume":"288","author":"Jackevicius","year":"2002","journal-title":"JAMA."},{"issue":"4","key":"10.1016\/j.zefq.2017.04.001_bib0400","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jama.288.4.455","article-title":"Long-term persistence in use of statin therapy in elderly patients","volume":"288","author":"Benner","year":"2002","journal-title":"JAMA."},{"issue":"2","key":"10.1016\/j.zefq.2017.04.001_bib0405","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1161\/CIRCULATIONAHA.105.505636","article-title":"Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease","volume":"113","author":"Newby","year":"2006","journal-title":"Circulation."},{"issue":"9","key":"10.1016\/j.zefq.2017.04.001_bib0410","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1345\/aph.1P150","article-title":"Predictors of nonadherence to statins: a systematic review and meta-analysis","volume":"44","author":"Mann","year":"2010","journal-title":"Ann Pharmacother."},{"key":"10.1016\/j.zefq.2017.04.001_bib0415","series-title":"Daten zum Gesundheitswesen","article-title":"Versicherte","author":"Gottfried","year":"2014"},{"issue":"2","key":"10.1016\/j.zefq.2017.04.001_bib0420","first-page":"59","article-title":"Der Bundes-Gesundheitssurvey 1997\/98","volume":"60","author":"Bellach","year":"1998","journal-title":"Gesundheitswesen."},{"issue":"5","key":"10.1016\/j.zefq.2017.04.001_bib0425","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00103-009-0843-3","article-title":"Health monitoring at the Robert Koch Institute. Status and perspectives","volume":"52","author":"Kurth","year":"2009","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz."},{"issue":"5\u20136","key":"10.1016\/j.zefq.2017.04.001_bib0430","first-page":"611","article-title":"The first wave of the German Health Interview and Examination Survey for Adults (DEGS1): participant recruitment, fieldwork, and quality management","volume":"56","author":"Gosswald","year":"2013","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"10.1016\/j.zefq.2017.04.001_bib0435","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1186\/1471-2458-12-730","article-title":"German health interview and examination survey for adults (DEGS) - design, objectives and implementation of the first data collection wave","volume":"12","author":"Scheidt-Nave","year":"2012","journal-title":"BMC Public Health."},{"issue":"6\u20137","key":"10.1016\/j.zefq.2017.04.001_bib0440","first-page":"775","article-title":"DEGS: German Health Interview and Examination Survey for Adults. A nationwide cross-sectional and longitudinal study within the framework of health monitoring conducted by the Robert Koch Institute","volume":"55","author":"Gosswald","year":"2012","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz."},{"issue":"3","key":"10.1016\/j.zefq.2017.04.001_bib0445","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/1099-1557(200005\/06)9:3<221::AID-PDS499>3.0.CO;2-P","article-title":"Consumption of calcium antagonists: results of the German national health surveys","volume":"9","author":"Knopf","year":"2000","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"5\u20136","key":"10.1016\/j.zefq.2017.04.001_bib0450","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1007\/s00103-013-1667-8","article-title":"Medication use of adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)","volume":"56","author":"Knopf","year":"2013","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz."},{"key":"10.1016\/j.zefq.2017.04.001_bib0455","unstructured":"Fricke U, G\u00fcnther J, Zawinell A. ATC-Klassifikation mit Tagesdosen f\u00fcr den deutschen Arzneimittelmarkt des GKV-Arzneimittelindex (Methodik und Liste der ATC-Codes mit DDD)2008. Available from: http:\/\/www.wido.de\/arz_atcddd-klassifi.html."},{"year":"2003","series-title":"The CAS - MIN educational classification in international comparative research","author":"Brauns","key":"10.1016\/j.zefq.2017.04.001_bib0460"},{"year":"2014","series-title":"Daten und Fakten: Ergebnisse der Studie \u00bbGesundheit in Deutschland aktuell 2012","author":"Koch-Institut","key":"10.1016\/j.zefq.2017.04.001_bib0465"},{"issue":"5\u20136","key":"10.1016\/j.zefq.2017.04.001_bib0470","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s00103-012-1650-9","article-title":"The first wave of the German Health Interview and Examination Survey for Adults (DEGS1): sample design, response, weighting and representativeness","volume":"56","author":"Kamtsiuris","year":"2013","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"issue":"9","key":"10.1016\/j.zefq.2017.04.001_bib0475","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1345\/aph.1L181","article-title":"Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines","volume":"42","author":"Mann","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.zefq.2017.04.001_bib0480","first-page":"1","article-title":"Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012","volume":"177","author":"Gu","year":"2014","journal-title":"NCHS Data Brief."},{"issue":"2","key":"10.1016\/j.zefq.2017.04.001_bib0485","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2125.2004.02256.x","article-title":"The influence of guidelines on the use of statins: analysis of prescribing trends 1998-2002","volume":"59","author":"Teeling","year":"2005","journal-title":"Br J Clin Pharmacol."},{"issue":"6","key":"10.1016\/j.zefq.2017.04.001_bib0490","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2796.2006.01730.x","article-title":"Time trends in population cholesterol levels 1986-2004: influence of lipid-lowering drugs, obesity, smoking and educational level. The northern Sweden MONICA study","volume":"260","author":"Eliasson","year":"2006","journal-title":"J Intern Med."},{"key":"10.1016\/j.zefq.2017.04.001_bib0495","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/CLEP.S104258","article-title":"Time trends in the prescription of statins for the primary prevention of cardiovascular disease in the United Kingdom: a cohort study using The Health Improvement Network primary care data","volume":"8","author":"O\u2019Keeffe","year":"2016","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.zefq.2017.04.001_bib0500","series-title":"Arzneiverordnungs-Report 2010 Aktuelle Daten, Kosten, Trends und Kommentare","first-page":"444","article-title":"Lipidsenkende Mittel","author":"Klose","year":"2000"},{"key":"10.1016\/j.zefq.2017.04.001_bib0505","series-title":"Arzneiverordnungs-Report 2010 Aktuelle Daten, Kosten, Trends","first-page":"933","article-title":"Arzneimittelverordnungen nach Alter und Geschlecht","author":"Coca","year":"2010"},{"key":"10.1016\/j.zefq.2017.04.001_bib0510","doi-asserted-by":"crossref","unstructured":"Mangiapane S, Agustin J, Riens B, Schulz. M., von Stillfried D. Medizinische Versorgung im regionalen Vergleich Vorstellung des Webportals www.versorgungsatlas.de. Gesundheitswesen. 2013; 75 - V10.","DOI":"10.1055\/s-0033-1337461"},{"key":"10.1016\/j.zefq.2017.04.001_bib0515","unstructured":"Mangiapane S. Untersuchung der medikament\u00f6sen Sekund\u00e4rpr\u00e4vention nach Myokardinfarkt auf Grundlage von GKV-Abrechnungsdaten. Doctorial Thesis. Berlin: Technische Universit\u00e4t Berlin, Fakult\u00e4t VII - Wirtschaft und Management; 2008. Available from: http:\/\/dx.doi.org\/10.14279\/depositonce-1846."},{"issue":"1","key":"10.1016\/j.zefq.2017.04.001_bib0520","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.amjcard.2014.09.041","article-title":"Gender disparities in evidence-based statin therapy in patients with cardiovascular disease","volume":"115","author":"Virani","year":"2015","journal-title":"Am J Cardiol."},{"issue":"5","key":"10.1016\/j.zefq.2017.04.001_bib0525","doi-asserted-by":"crossref","first-page":"e0155228","DOI":"10.1371\/journal.pone.0155228","article-title":"Drivers of the Sex Disparity in Statin Therapy in Patients with Coronary Artery Disease: A Cohort Study","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS One."},{"issue":"5\u20136","key":"10.1016\/j.zefq.2017.04.001_bib0530","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00103-013-1670-0","article-title":"Prevalence of dyslipidemia among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS 1)","volume":"56","author":"Scheidt-Nave","year":"2013","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz."},{"issue":"5","key":"10.1016\/j.zefq.2017.04.001_bib0535","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/CIRCULATIONAHA.114.012477","article-title":"Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease","volume":"131","author":"Navar-Boggan","year":"2015","journal-title":"Circulation."},{"issue":"7","key":"10.1016\/j.zefq.2017.04.001_bib0540","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1194\/jlr.P049064","article-title":"Lipoprotein subclasses and endogenous sex hormones in women at midlife","volume":"55","author":"El Khoudary","year":"2014","journal-title":"J Lipid Res."},{"issue":"1","key":"10.1016\/j.zefq.2017.04.001_bib0545","doi-asserted-by":"crossref","first-page":"e000135","DOI":"10.1136\/bmjdrc-2015-000135","article-title":"Changes in diabetes care indicators: findings from German National Health Interview and Examination Surveys 1997-1999 and 2008-2011","volume":"3","author":"Du","year":"2015","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"1","key":"10.1016\/j.zefq.2017.04.001_bib0550","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009217.pub2","article-title":"Statins for the primary prevention of cardiovascular disease","author":"Taylor","year":"2013","journal-title":"Cochrane Database Syst Rev."},{"issue":"25 Suppl 2","key":"10.1016\/j.zefq.2017.04.001_bib0555","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation."},{"key":"10.1016\/j.zefq.2017.04.001_bib0560","unstructured":"Endres M, Diener H, R\u00f6ther J, Behnke M. Sekund\u00e4rprophylaxe isch\u00e4mischer Schlaganfall und TIA \u2013 Teil 1. S3-Leitlinie 2015. Available from: http:\/\/www.dgn.org\/leitlinien\/3024-ll-23-ll-sekundaerprophylaxe-ischaemischer-schlaganfall-und-transitorische-ischaemische-attacke."},{"key":"10.1016\/j.zefq.2017.04.001_bib0565","unstructured":"Laufs U, Donner N, Haasenritter J, Werdan K, Jacobshagen C, Fleck E, et al. Nationale Versorgungsleitlinie Chronische KHK. Langfassung2016; 4(1). Available from: http:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/nvl-004l_S3_KHK_2016-02.pdf."},{"issue":"50","key":"10.1016\/j.zefq.2017.04.001_bib0570","first-page":"856","article-title":"Prescription Prevalence and Continuing Medication Use for Secondary Prevention After Myocardial Infarction: the Reality of Care Revealed by Claims Data Analysis","volume":"108","author":"Mangiapane","year":"2011","journal-title":"Dtsch Arztebl Int."},{"issue":"4","key":"10.1016\/j.zefq.2017.04.001_bib0575","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.hrtlng.2015.02.004","article-title":"Adherence to evidence-based secondary prevention pharmacotherapy in patients after an acute coronary syndrome: A systematic review","volume":"44","author":"Chen","year":"2015","journal-title":"Heart Lung."},{"issue":"3","key":"10.1016\/j.zefq.2017.04.001_bib0580","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/dmrr.1293","article-title":"Discontinuation of statins among patients with type 2 diabetes","volume":"28","author":"Lamberts","year":"2012","journal-title":"Diabetes Metab Res Rev."},{"key":"10.1016\/j.zefq.2017.04.001_bib0585","doi-asserted-by":"crossref","first-page":"f2610","DOI":"10.1136\/bmj.f2610","article-title":"Risk of incident diabetes among patients treated with statins: population based study","volume":"346","author":"Carter","year":"2013","journal-title":"BMJ."},{"key":"10.1016\/j.zefq.2017.04.001_bib0590","doi-asserted-by":"crossref","first-page":"g3652","DOI":"10.1136\/bmj.g3652","article-title":"(Mis)interpreting studies on the adverse effects of statins","volume":"348","author":"Zhang","year":"2014","journal-title":"BMJ."},{"key":"10.1016\/j.zefq.2017.04.001_bib0595","doi-asserted-by":"crossref","unstructured":"Stavrou EP, Buckley N, Olivier J, Pearson SA. Discontinuation of statin therapy in older people: does a cancer diagnosis make a difference? An observational cohort study using data linkage. BMJ Open [Internet]. 2012 PMC3358623]; 2(3). Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22614172.","DOI":"10.1136\/bmjopen-2012-000880"},{"issue":"4","key":"10.1016\/j.zefq.2017.04.001_bib0600","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/jcsm.12109","article-title":"Discussion around statin discontinuation in older adults and patients with wasting diseases","volume":"7","author":"Banach","year":"2016","journal-title":"J Cachexia Sarcopenia Muscle."}],"container-title":["Zeitschrift f\u00fcr Evidenz, Fortbildung und Qualit\u00e4t im Gesundheitswesen"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1865921717300478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1865921717300478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T12:30:13Z","timestamp":1569328213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1865921717300478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":60,"alternative-id":["S1865921717300478"],"URL":"https:\/\/doi.org\/10.1016\/j.zefq.2017.04.001","relation":{},"ISSN":["1865-9217"],"issn-type":[{"type":"print","value":"1865-9217"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Zeitliche Entwicklung der Anwendungspr\u00e4valenz von Statinen in Deutschland \u2013 Ergebnisse der nationalen Interview- und Untersuchungssurveys 1997-1999 und 2008-2011","name":"articletitle","label":"Article Title"},{"value":"Zeitschrift f\u00fcr Evidenz, Fortbildung und Qualit\u00e4t im Gesundheitswesen","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.zefq.2017.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}